Sandoz To Pay $195M For Generic-Drug Antitrust Violations
The U.S. Department of Justice announced Monday that Sandoz will pay a $195 million criminal penalty under a deferred prosecution agreement for generic-drug price-fixing, which will spare the company from being...To view the full article, register now.
Already a subscriber? Click here to view full article